Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Non-Human Primates of the Anti-PD-1 Antibody Pembrolizumab.

Hutchins B, Starling GC, McCoy MA, Herzyk D, Poulet FM, Dulos J, Liu L, Kang SP, Fayadat-Dilman L, Hsieh M, Andrews CL, Ayanoglu G, Cullen C, De Waal Malefyt R, Kastelein RA, Le Saux S, Lee J, Li S, Malashock D, Sadekova S, Soder G, van Eenennaam H, Willingham A, Yu Y, Streuli M, Carven GJ, van Elsas A.

Mol Cancer Ther. 2020 Mar 30. pii: molcanther.0774.2019. doi: 10.1158/1535-7163.MCT-19-0774. [Epub ahead of print]


Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape.

Martin CJ, Datta A, Littlefield C, Kalra A, Chapron C, Wawersik S, Dagbay KB, Brueckner CT, Nikiforov A, Danehy FT Jr, Streich FC Jr, Boston C, Simpson A, Jackson JW, Lin S, Danek N, Faucette RR, Raman P, Capili AD, Buckler A, Carven GJ, Schürpf T.

Sci Transl Med. 2020 Mar 25;12(536). pii: eaay8456. doi: 10.1126/scitranslmed.aay8456.


Structural basis for specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015.

Dagbay KB, Treece E, Streich FC Jr, Jackson JW, Faucette RR, Nikiforov A, Lin SC, Boston CJ, Nicholls SB, Capili AD, Carven GJ.

J Biol Chem. 2020 Feb 19. pii: jbc.RA119.012293. doi: 10.1074/jbc.RA119.012293. [Epub ahead of print]


A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation.

Cote SM, Jackson J, Pirruccello-Straub M, Carven GJ, Wawersik S.

SLAS Discov. 2020 Jan;25(1):95-103. doi: 10.1177/2472555219860779. Epub 2019 Jul 26.


Blocking extracellular activation of myostatin as a strategy for treating muscle wasting.

Pirruccello-Straub M, Jackson J, Wawersik S, Webster MT, Salta L, Long K, McConaughy W, Capili A, Boston C, Carven GJ, Mahanthappa NK, Turner KJ, Donovan A.

Sci Rep. 2018 Feb 2;8(1):2292. doi: 10.1038/s41598-018-20524-9.


Characterization of binding mode of action of a blocking anti-platelet-derived growth factor (PDGF)-B monoclonal antibody, MOR8457, reveals conformational flexibility and avidity needed for PDGF-BB to bind PDGF receptor-β.

Kuai J, Mosyak L, Brooks J, Cain M, Carven GJ, Ogawa S, Ishino T, Tam M, Lavallie ER, Yang Z, Ponsel D, Rauchenberger R, Arch R, Pullen N.

Biochemistry. 2015 Mar 17;54(10):1918-29. doi: 10.1021/bi5015425. Epub 2015 Mar 6.


PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.

Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, Gorecka MA, de Haan AF, Mulders P, Punt CJ, Jacobs JF, Schalken JA, Oosterwijk E, van Eenennaam H, Boots AM.

J Immunother. 2012 Feb-Mar;35(2):169-78. doi: 10.1097/CJI.0b013e318247a4e7.


Proteomic analysis of microglia-derived exosomes: metabolic role of the aminopeptidase CD13 in neuropeptide catabolism.

Potolicchio I, Carven GJ, Xu X, Stipp C, Riese RJ, Stern LJ, Santambrogio L.

J Immunol. 2005 Aug 15;175(4):2237-43.


Induced fit of an epitope peptide to a monoclonal antibody probed with a novel parallel surface plasmon resonance assay.

Baggio R, Carven GJ, Chiulli A, Palmer M, Stern LJ, Arenas JE.

J Biol Chem. 2005 Feb 11;280(6):4188-94. Epub 2004 Nov 18.


Monoclonal antibodies specific for the empty conformation of HLA-DR1 reveal aspects of the conformational change associated with peptide binding.

Carven GJ, Chitta S, Hilgert I, Rushe MM, Baggio RF, Palmer M, Arenas JE, Strominger JL, Horejsi V, Santambrogio L, Stern LJ.

J Biol Chem. 2004 Apr 16;279(16):16561-70. Epub 2004 Feb 2.


Extracellular antigen processing and presentation by immature dendritic cells.

Santambrogio L, Sato AK, Carven GJ, Belyanskaya SL, Strominger JL, Stern LJ.

Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15056-61.

Supplemental Content

Loading ...
Support Center